Open Access
Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
Liubov I. Kozlovskaya
1, 2
,
Anastasia N. Piniaeva
1
,
Georgy M. Ignatyev
1
,
Ilya V. Gordeychuk
1, 2
,
Viktor P. Volok
1, 3
,
Yulia V. Rogova
1
,
Anna A. Shishova
1, 2
,
Anastasia A. Kovpak
1
,
Yury Yu. Ivin
1
,
Liliya P. Antonova
1
,
Kirill M. Mefyod
1
,
Lyubov S. Prokosheva
1
,
Anna S. Sibirkina
1
,
Yuliya Yu. Tarasova
1
,
Olga S. Gancharova
1
,
Victoria V. Illarionova
1
,
Grigory S. Glukhov
3
,
Olga S. Sokolova
3
,
Konstantin V. Shaitan
3
,
Stanislav A. Gulyaev
1
,
Tatiana V. Gulyaeva
1
,
Andrey V. Moroz
1
,
Larissa V. Gmyl
1
,
Elena G. Ipatova
1
,
Mikhail P. Kirpichnikov
3
,
Alexey M. Egorov
1, 3
,
Aleksandra A. Siniugina
1
,
Publication type: Journal Article
Publication date: 2021-01-01
scimago Q1
wos Q1
SJR: 2.264
CiteScore: 13.9
Impact factor: 7.5
ISSN: 22221751
PubMed ID:
34427172
Drug Discovery
General Medicine
Microbiology
Infectious Diseases
Immunology
Epidemiology
Parasitology
Virology
Abstract
ABSTRACT The unprecedented in recent history global COVID-19 pandemic urged the implementation of all existing vaccine platforms to ensure the availability of the vaccines against COVID-19 to every country in the world. Despite the multitude of high-quality papers describing clinical trials of different vaccine products, basic detailed data on general toxicity, reproductive toxicity, immunogenicity, protective efficacy and durability of immune response in animal models are scarce. Here, we developed a β-propiolactone-inactivated whole virion vaccine CoviVac and assessed its safety, protective efficacy, immunogenicity and stability of the immune response in rodents and non-human primates. The vaccine showed no signs of acute/chronic, reproductive, embryo- and fetotoxicity, or teratogenic effects, as well as no allergenic properties in studied animal species. The vaccine induced stable and robust humoral immune response both in form of specific anti-SARS-CoV-2 IgG and NAbs in mice, Syrian hamsters, and common marmosets. The NAb levels did not decrease significantly over the course of one year. The course of two immunizations protected Syrian hamsters from severe pneumonia upon intranasal challenge with the live virus. Robustness of the vaccine manufacturing process was demonstrated as well. These data encouraged further evaluation of CoviVac in clinical trials.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
|
|
|
Vaccines
6 publications, 9.09%
|
|
|
Viruses
6 publications, 9.09%
|
|
|
International Journal of Molecular Sciences
3 publications, 4.55%
|
|
|
Acta Naturae
2 publications, 3.03%
|
|
|
Epidemiology and Vaccinal Prevention (Epidemiologiya i Vaktsinoprofilaktika)
2 publications, 3.03%
|
|
|
Medical academic journal
2 publications, 3.03%
|
|
|
Microscopy Research and Technique
1 publication, 1.52%
|
|
|
Journal of microbiology epidemiology immunobiology
1 publication, 1.52%
|
|
|
Immunotherapy
1 publication, 1.52%
|
|
|
Toxicologic Pathology
1 publication, 1.52%
|
|
|
International Journal of Environmental Research and Public Health
1 publication, 1.52%
|
|
|
Frontiers in Drug Discovery
1 publication, 1.52%
|
|
|
Frontiers in Materials
1 publication, 1.52%
|
|
|
Pharmaceutics
1 publication, 1.52%
|
|
|
COVID
1 publication, 1.52%
|
|
|
Pathogens
1 publication, 1.52%
|
|
|
Cellular and Molecular Biology Letters
1 publication, 1.52%
|
|
|
Archives of Virology
1 publication, 1.52%
|
|
|
BMC Public Health
1 publication, 1.52%
|
|
|
Respiratory Research
1 publication, 1.52%
|
|
|
Infection, Genetics and Evolution
1 publication, 1.52%
|
|
|
Vaccine
1 publication, 1.52%
|
|
|
Journal of Drug Delivery Science and Technology
1 publication, 1.52%
|
|
|
Journal of Controlled Release
1 publication, 1.52%
|
|
|
iScience
1 publication, 1.52%
|
|
|
Molecular Biology
1 publication, 1.52%
|
|
|
Health Science Reports
1 publication, 1.52%
|
|
|
Herald of the Russian Academy of Sciences
1 publication, 1.52%
|
|
|
Cardiovascular Therapy and Prevention (Russian Federation)
1 publication, 1.52%
|
|
|
1
2
3
4
5
6
|
Publishers
|
2
4
6
8
10
12
14
16
18
20
|
|
|
MDPI
19 publications, 28.79%
|
|
|
Elsevier
9 publications, 13.64%
|
|
|
Springer Nature
6 publications, 9.09%
|
|
|
Wiley
4 publications, 6.06%
|
|
|
Frontiers Media S.A.
4 publications, 6.06%
|
|
|
Cold Spring Harbor Laboratory
3 publications, 4.55%
|
|
|
Pleiades Publishing
2 publications, 3.03%
|
|
|
Acta Naturae Ltd
2 publications, 3.03%
|
|
|
LLC Numicom
2 publications, 3.03%
|
|
|
Eco-Vector LLC
2 publications, 3.03%
|
|
|
Central Research Institute for Epidemiology
1 publication, 1.52%
|
|
|
Taylor & Francis
1 publication, 1.52%
|
|
|
SAGE
1 publication, 1.52%
|
|
|
Silicea - Poligraf, LLC
1 publication, 1.52%
|
|
|
SCEEMP
1 publication, 1.52%
|
|
|
SPb RAACI
1 publication, 1.52%
|
|
|
Alfmed LLC
1 publication, 1.52%
|
|
|
Scientific Center of Neurology
1 publication, 1.52%
|
|
|
National Library of Serbia
1 publication, 1.52%
|
|
|
Reaviz Medical University
1 publication, 1.52%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 1.52%
|
|
|
The Russian Academy of Sciences
1 publication, 1.52%
|
|
|
2
4
6
8
10
12
14
16
18
20
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
66
Total citations:
66
Citations from 2024:
11
(16%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Kozlovskaya L. I. et al. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies // Emerging Microbes & Infections. 2021. Vol. 10. No. 1. pp. 1790-1806.
GOST all authors (up to 50)
Copy
Kozlovskaya L. I., Piniaeva A. N., Ignatyev G. M., Gordeychuk I. V., Volok V. P., Rogova Y. V., Shishova A. A., Kovpak A. A., Ivin Y. Y., Antonova L. P., Mefyod K. M., Prokosheva L. S., Sibirkina A. S., Tarasova Y. Y., Bayurova E. O., Gancharova O. S., Illarionova V. V., Glukhov G. S., Sokolova O. S., Shaitan K. V., Moysenovich A. M., Gulyaev S. A., Gulyaeva T. V., Moroz A. V., Gmyl L. V., Ipatova E. G., Kirpichnikov M. P., Egorov A. M., Siniugina A. A., Ishmukhametov A. A. Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies // Emerging Microbes & Infections. 2021. Vol. 10. No. 1. pp. 1790-1806.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1080/22221751.2021.1971569
UR - https://doi.org/10.1080/22221751.2021.1971569
TI - Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
T2 - Emerging Microbes & Infections
AU - Kozlovskaya, Liubov I.
AU - Piniaeva, Anastasia N.
AU - Ignatyev, Georgy M.
AU - Gordeychuk, Ilya V.
AU - Volok, Viktor P.
AU - Rogova, Yulia V.
AU - Shishova, Anna A.
AU - Kovpak, Anastasia A.
AU - Ivin, Yury Yu.
AU - Antonova, Liliya P.
AU - Mefyod, Kirill M.
AU - Prokosheva, Lyubov S.
AU - Sibirkina, Anna S.
AU - Tarasova, Yuliya Yu.
AU - Bayurova, Ekaterina O.
AU - Gancharova, Olga S.
AU - Illarionova, Victoria V.
AU - Glukhov, Grigory S.
AU - Sokolova, Olga S.
AU - Shaitan, Konstantin V.
AU - Moysenovich, Anastasia M.
AU - Gulyaev, Stanislav A.
AU - Gulyaeva, Tatiana V.
AU - Moroz, Andrey V.
AU - Gmyl, Larissa V.
AU - Ipatova, Elena G.
AU - Kirpichnikov, Mikhail P.
AU - Egorov, Alexey M.
AU - Siniugina, Aleksandra A.
AU - Ishmukhametov, Aydar A.
PY - 2021
DA - 2021/01/01
PB - Taylor & Francis
SP - 1790-1806
IS - 1
VL - 10
PMID - 34427172
SN - 2222-1751
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2021_Kozlovskaya,
author = {Liubov I. Kozlovskaya and Anastasia N. Piniaeva and Georgy M. Ignatyev and Ilya V. Gordeychuk and Viktor P. Volok and Yulia V. Rogova and Anna A. Shishova and Anastasia A. Kovpak and Yury Yu. Ivin and Liliya P. Antonova and Kirill M. Mefyod and Lyubov S. Prokosheva and Anna S. Sibirkina and Yuliya Yu. Tarasova and Ekaterina O. Bayurova and Olga S. Gancharova and Victoria V. Illarionova and Grigory S. Glukhov and Olga S. Sokolova and Konstantin V. Shaitan and Anastasia M. Moysenovich and Stanislav A. Gulyaev and Tatiana V. Gulyaeva and Andrey V. Moroz and Larissa V. Gmyl and Elena G. Ipatova and Mikhail P. Kirpichnikov and Alexey M. Egorov and Aleksandra A. Siniugina and Aydar A. Ishmukhametov},
title = {Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies},
journal = {Emerging Microbes & Infections},
year = {2021},
volume = {10},
publisher = {Taylor & Francis},
month = {jan},
url = {https://doi.org/10.1080/22221751.2021.1971569},
number = {1},
pages = {1790--1806},
doi = {10.1080/22221751.2021.1971569}
}
Cite this
MLA
Copy
Kozlovskaya, Liubov I., et al. “Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies.” Emerging Microbes & Infections, vol. 10, no. 1, Jan. 2021, pp. 1790-1806. https://doi.org/10.1080/22221751.2021.1971569.